Scarica l'app Stockscreener
23.57
1.99%
0.46
Dopo l'orario di chiusura:
23.99
0.42
+1.78%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 - marketscreener.com
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Denali Therapeutics Inc. Revenue Breakdown – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DNLI Maintained by Morgan Stanley -- Price Target Raised to $36 - GuruFocus
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36 - Moomoo
DNLI|Denali Therapeutics Inc|Price:23.110|Chg%:-0.310 - TradingKey
Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey? - Yahoo Finance
Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline - Ad-hoc-news.de
Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval? - Yahoo Finance
Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return - Sahm
Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily
Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35 - Moomoo
DENALI THERAPEUTICS INC. : DEUTSCHE BANK RAISES TARGET PRICE TO $35 FROM $31 - Bitget
Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC) - The Globe and Mail
Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating - marketscreener.com
Will Recent Setbacks Impact Growth Prospects of DNLI Stock? - Yahoo Finance
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $31 - Moomoo
Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail
Denali Therapeutics (DNLI) Faces 12.4% Decline in Share Value - GuruFocus
Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan - Moomoo
Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating - Moomoo
Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg - GuruFocus
JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating By Investing.com - Investing.com Nigeria
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Stocktwits
JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating - Investing.com
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? -- Barrons.com - Moomoo
Denali Therapeutics (DNLI) Investor Day 2025 Summary - Quartr
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI) - Sahm
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier - The Manila Times
Denali CEO to keynote AAIC 2026, highlighting a... - Pluang
Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s - Stock Titan
Denali Therapeutics stock hits 52-week high at $26.95 By Investing.com - Investing.com South Africa
Denali Therapeutics stock hits 52-week high at $26.95 - Investing.com
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - Yahoo Finance
T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A - Stock Titan
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
DNLIDenali Therapeutics Inc Volatility & Greeks - Finviz
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - Sahm
Denali Therapeutics stock stays focused on pipeline progress. - ad-hoc-news.de
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com
Denali to sell priority review voucher for $195M cash boost - MSN
Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh - TradingView
Price to earnings forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to book forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI) - TradingView
Enterprise value to EBITDA forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):